DGIdb - FGFR1 Gene Record

FGFR1 2260 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

2260
FIBROBLAST GROWTH FACTOR RECEPTOR 1
FGFR1
BFGFR
CD331
CEK
ECCL
FGFBR
FGFR-1
FLG
FLT-2
FLT2
HBGFR
HH2
HRTFDS
KAL2
N-SAM
OGD
bFGF-R-1
136350
3688
ENSG00000077782
OTTHUMG00000147366
PA28127
1885
BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 PRECURSOR (EC 2.7.1.112) (FGFR-1) (BFGF-R) (FMS-LIKE TYROSINE KINASE-2) (C-FGR). [SOURCE:UNIPROT/SWISSPROT;ACC:P11362]
P11362
FGFR1_HUMAN
CD_antigen=CD331
Proto-oncogene c-Fgr
Fms-like tyrosine kinase 2
Basic fibroblast growth factor receptor 1
FGFR1-3
T47101

Gene Info:

CancerCommons Reported Gene Name	FGFRs
Human Readable Name	DRUGGABLE GENOME
Uniprot Evidence	1: Evidence at protein level
Uniprot Status	Swiss-Prot
Interpro Type	Domain
Interpro Name	Serine-threonine/tyrosine-protein kinase catalytic domain
Interpro Acc	IPR001245
Human Readable Name	KINASE
Interpro Short Name	Ser-Thr/Tyr_kinase_cat_dom
Initial Gene Query	FGFR1
Counted Citations from 1950-2000	1239
Target Class	Receptors
Target Subclass	EC:2.7.10.1
Gene Biotype	PROTEIN_CODING

(24 More Sources)

Gene Categories: Category Details

KINASE
TYROSINE KINASE
DRUG RESISTANCE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE

Publications:

Mayer et al., 2017, A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer., Clin. Cancer Res.
Soria et al., 2014, Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors., Ann. Oncol.
Singhi et al., 2017, Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma., J Natl Compr Canc Netw
Matsubara et al., 1999, Hormone Refractory Prostate Cancer and Fibroblast Growth Factor Receptor., Breast Cancer
Sher et al., 2000, Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7., J. Biol. Chem.
Wang et al., 1999, Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex., Biochemistry
Ostrovsky et al., 2002, Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes., J. Biol. Chem.
Lu et al., 1999, Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate., J. Biol. Chem.
Singh et al., 2012, Transforming fusions of FGFR and TACC genes in human glioblastoma., Science
Nogova et al., 2017, Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study., J. Clin. Oncol.
Göke et al., 2015, FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers., Clin. Cancer Res.
Chudasama et al., 2017, Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma., Clin. Cancer Res.
Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet
André et al., 2013, Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer., Clin. Cancer Res.
Lim et al., 2016, Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study., Cancer
Chase et al., 2007, Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome., Blood
Tohyama et al., 2014, Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models., J Thyroid Res
Matsui et al., 2008, E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition., Int. J. Cancer
Singleton et al., 2015, Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC., Cancer Res.
Sáez et al., 1999, Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride., Prostate
Chen et al., 2004, PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder., Proc. Natl. Acad. Sci. U.S.A.
Ho et al., 2015, The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma., BMC Cancer
Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics
Carlomagno et al., 2006, BAY 43-9006 inhibition of oncogenic RET mutants., J. Natl. Cancer Inst.
Wilhelm et al., 2004, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis., Cancer Res.
Wilhelm et al., 2006, Discovery and development of sorafenib: a multikinase inhibitor for treating cancer., Nat Rev Drug Discov
Wynes et al., 2014, FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies., Clin. Cancer Res.
Agelopoulos et al., 2015, Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma., Clin. Cancer Res.
Ren et al., 2013, Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1., Oncol. Rep.
Gozgit et al., 2013, Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models., Cancer Chemother. Pharmacol.
2015, Let's be pragmatic about clinical data., Sci Data
Wang et al., 2017, A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma., Eur. Urol.
Perera et al., 2017, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor., Mol. Cancer Ther.
Tabernero et al., 2015, Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors., J. Clin. Oncol.
Nishina T et al., 2018, Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors., Invest New Drugs
Grünewald S et al., 2019, Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models., Int J Cancer
Liu PCC et al., 2020, INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models., PLoS One
Nakanishi et al., 2015, ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor., Mol. Cancer Ther.
Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
Tang et al., 2006, Ethanol inhibits L1 cell adhesion molecule activation of mitogen-activated protein kinases., J. Neurochem.
McLeskey et al., 1994, MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands., Cancer Res.
Watanabe Miyano et al., 2016, E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models., Mol. Cancer Ther.
Turner et al., 2010, FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer., Cancer Res.
Malchers F et al., 2014, Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer., Cancer Discov
Harding et al., 2013, Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer., Sci Transl Med
Szlachcic A et al., 2012, FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation., Int J Nanomedicine
Jo et al., 2015, Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity., Mol. Cancer Ther.
Koole et al., 2016, FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma., Clin. Cancer Res.
Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.
Manchado et al., 2016, A combinatorial strategy for treating KRAS-mutant lung cancer., Nature

FP-1039 FGFR1

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name FP-1039

Novel drug target Established target

Indication/Tumor Type lung cancer

PMIDs:
23226697 23536011

Sources:
TdgClinicalTrial JAX-CKB TTD
E-7090 FGFR1

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
7506125 27535969

Sources:
JAX-CKB
ERDAFITINIB FGFR1

Interaction Score: 0.73

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Phase I

PMIDs:
28341788 26324363 28965185

Sources:
JAX-CKB TTD OncoKB
PALIFERMIN FGFR1

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
11091737 10950949 9890894 11714710 10212269

Sources:
TdgClinicalTrial
LUCITANIB FGFR1

Interaction Score: 0.73

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy Alpelisib + Lucitanib

Indication/Tumor Type estrogen-receptor positive breast cancer

Response Type sensitive

PMIDs:
27126994 25193991

Sources:
JAX-CKB ChemblInteractions CIViC MyCancerGenomeClinicalTrial
ROGARATINIB FGFR1

Interaction Score: 0.58

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type hemangioma

Evidence Type Actionable

Approval Status Phase I

PMIDs:
30807645

Sources:
JAX-CKB ChemblInteractions CIViC
PEMIGATINIB FGFR1

Interaction Score: 0.48

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
32315352

Sources:
JAX-CKB
INFIGRATINIB FGFR1

Interaction Score: 0.43

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Notes

Indication/Tumor Type uterus leiomyosarcoma

PMIDs:
22837387 27870574 26015511 27535980

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial TTD OncoKB
DERAZANTINIB FGFR1

Interaction Score: 0.36

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
CHEMBL459729 FGFR1

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
BRIVANIB FGFR1

Interaction Score: 0.33

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type no benefit

Approval Status Preclinical

PMIDs:
22238366 20124951

Sources:
JAX-CKB ChemblInteractions PharmGKB
PONATINIB FGFR1

Interaction Score: 0.33

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Indication/Tumor Type extraosseous Ewing's sarcoma

Response Type sensitive

PMIDs:
24771645 22238366 26179511 23563700 23468082 26175911

Sources:
TALC MyCancerGenome JAX-CKB CIViC
NINTEDANIB FGFR1

Interaction Score: 0.31

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Indication/Tumor Type Advanced Solid Tumor

Response Type decreased response

PMIDs:
18559524 22238366 31016670

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TTD
SURUFATINIB FGFR1

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor 1 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
PHA-665752 FGFR1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type hepatocellular carcinoma

Response Type no benefit

Approval Status Preclinical - Cell culture

PMIDs:
26351320

Sources:
JAX-CKB
DEBIO-1347 FGFR1

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
OncoKB
LENVATINIB FGFR1

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
25295214 17943726

Sources:
TdgClinicalTrial JAX-CKB
ALECTINIB FGFR1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type pancreatic ductal adenocarcinoma

Response Type predicted – sensitive

Approval Status Clinical Study

PMIDs:
28476735

Sources:
JAX-CKB
RO-4987655 FGFR1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Indication/Tumor Type lung small cell carcinoma

Evidence Type Actionable

PMIDs:
26438159

Sources:
JAX-CKB
AZD-4547 FGFR1

Interaction Score: 0.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LY-2874455 FGFR1

Interaction Score: 0.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
FIBROBLAST GROWTH FACTOR-1 FGFR1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
VISTUSERTIB FGFR1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD4547 + Vistusertib

Indication/Tumor Type head and neck squamous cell carcinoma

Response Type sensitive

PMIDs:
26359452

Sources:
JAX-CKB
TRAFERMIN FGFR1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name trafermin, fibro/

PMIDs:
None found

Sources:
TdgClinicalTrial
ORANTINIB FGFR1

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions
KW-2449 FGFR1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
AFIMOXIFENE FGFR1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20179196

Sources:
CIViC
FINASTERIDE FGFR1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10386468

Sources:
NCI
BRIVANIB ALANINATE FGFR1

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
AZD-8055 FGFR1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD4547 + AZD8055

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

PMIDs:
26359452

Sources:
JAX-CKB
CP-459632 FGFR1

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ROMIPLOSTIM FGFR1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
XL-228 FGFR1

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome
RABEPRAZOLE SODIUM FGFR1

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome TTD
DOVITINIB FGFR1

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
23658459 27315356 22238366 17698633

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB
NINTEDANIB ESYLATE FGFR1

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CRIZOTINIB FGFR1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type pancreatic ductal adenocarcinoma

Response Type resistant

Approval Status Clinical Study

PMIDs:
28476735

Sources:
JAX-CKB
MUPARFOSTAT FGFR1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Muparfostat

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
XL-999 FGFR1

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PAZOPANIB HYDROCHLORIDE FGFR1

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor 1 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SORAFENIB FGFR1

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Emerging

Approval Status Phase II

Response Type not applicable

PMIDs:
25900027 28362716 16507829 15466206 17016424

Sources:
JAX-CKB PharmGKB
BUPARLISIB FGFR1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD4547 + BKM120

Indication/Tumor Type transitional cell carcinoma

Response Type sensitive

PMIDs:
28108151

Sources:
JAX-CKB
MK-2461 FGFR1

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
ENMD-2076 FGFR1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ENMD-2076

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial ClearityFoundationClinicalTrial
MIDOSTAURIN FGFR1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15448205

Sources:
CIViC
PAZOPANIB FGFR1

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
24302556

Sources:
DTC CIViC
REGORAFENIB FGFR1

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor 1 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial
MASITINIB FGFR1

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
CEDIRANIB FGFR1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type decreased response

Approval Status Preclinical

PMIDs:
22238366

Sources:
DTC JAX-CKB
TG100-801 FGFR1

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Fibroblast growth factor receptor 1 inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
ALPELISIB FGFR1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Indication/Tumor Type estrogen-receptor positive breast cancer

PMIDs:
27126994

Sources:
JAX-CKB
SELUMETINIB FGFR1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung squamous cell carcinoma

Response Type no benefit

Approval Status Preclinical - Cell culture

PMIDs:
26438159

Sources:
JAX-CKB
TRAMETINIB FGFR1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung cancer

Response Type no benefit

Approval Status Preclinical

PMIDs:
27338794

Sources:
JAX-CKB
CHEMBL578061 FGFR1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ETOPOSIDE FGFR1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Etoposide + GSK3052230

Indication/Tumor Type lung small cell carcinoma

Response Type sensitive

PMIDs:
23536011

Sources:
JAX-CKB
PD-0166285 FGFR1

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Fibroblast growth factor receptor 1 inhibitor

PMIDs:
None found

Sources:
DTC ChemblInteractions
MLN-8054 FGFR1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ENMD-981693 FGFR1

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SIROLIMUS FGFR1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD4547 + Sirolimus

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

PMIDs:
26359452

Sources:
JAX-CKB
CHEMBL546797 FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
GEFITINIB FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD4547 + Gefitinib

Indication/Tumor Type head and neck squamous cell carcinoma

Response Type sensitive

PMIDs:
26936917

Sources:
JAX-CKB
AST-487 FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DOCETAXEL FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30807645

Sources:
CIViC
GW843682X FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
HESPERADIN FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
19035792

Sources:
DTC
ALISERTIB FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
GO-6976 FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OSI-632 FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ALCOHOL FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16478533

Sources:
NCI
RG-1530 FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor 1 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
DTC ChemblInteractions
ALSTERPAULLONE FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
JNJ-7706621 FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VANDETANIB FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ENTRECTINIB FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
GW441756X FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DASATINIB FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TOZASERTIB FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Etoposide + GSK3052230

Indication/Tumor Type lung small cell carcinoma

Response Type sensitive

PMIDs:
23536011

Sources:
JAX-CKB
R-406 FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SP-600125 FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CYC-116 FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TAE-684 FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ILORASERTIB FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PF-00562271 FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CENISERTIB FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

Ensembl: ENSG00000077782
- Version: 101_38
Alternate Names:

FGFR1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

RussLampel: ENSG00000077782

Version: 26-July-2011

Alternate Names:

FGFR1 Display Id

ENSG00000077782 Ensembl Gene Id

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 PRECURSOR (EC 2.7.1.112) (FGFR-1) (BFGF-R) (FMS-LIKE TYROSINE KINASE-2) (C-FGR). [SOURCE:UNIPROT/SWISSPROT;ACC:P11362] Description

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

CancerCommons: FGFR1
- Version: 25-July-2013
Alternate Names:

2260 Entrez Gene ID

Gene Info:

CancerCommons Reported Gene Name FGFRs

Publications:
TdgClinicalTrial: P11362
- Version: January-2014
Alternate Names:

FGFR1 Gene Symbol

Gene Info:

Target Class Receptors

Target Subclass EC:2.7.10.1

Publications:
HopkinsGroom: P11362
- Version: 11-September-2012
Alternate Names:

2260 Entrez Gene Id

FGFR1_HUMAN Uniprot Id

ENSG00000077782 Ensembl Gene Id

Gene Info:

Uniprot Evidence 1: Evidence at protein level

Uniprot Status Swiss-Prot

Human Readable Name DRUGGABLE GENOME

Gene Categories:

KINASE, DRUGGABLE GENOME

Publications:
BaderLabGenes: FGFR1
- Version: February-2014
Alternate Names:

2260 Entrez Gene ID

Gene Info:

Initial Gene Query FGFR1

Counted Citations from 1950-2000 1239

Gene Categories:

KINASE

Publications:

JAX-CKB: FGFR1

Version: 27-September-2017

Alternate Names:

2260 CKB Entrez Id

FGFR1 CKB Gene Synonym

bFGF-R-1 CKB Gene Synonym

Gene Info:

Publications:

Singhi et al., 2017, Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma., J Natl Compr Canc Netw

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.

André et al., 2013, Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer., Clin. Cancer Res.

PharmGKB: FGFR1
- Version: 18-August-2020
Alternate Names:

PA28127 PharmGKB ID

Gene Info:

Publications:

Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics

Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics

CIViC: FGFR1

Version: 14-September-2020

Alternate Names:

2260 Entrez Gene ID

1885 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Dutt et al., 2011, Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer., PLoS ONE

Weiss et al., 2010, Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer., Sci Transl Med

Chudasama et al., 2017, Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma., Clin. Cancer Res.

TTD: Fibroblast growth factor receptor 1
- Version: 2020.06.01
Alternate Names:

FGFR1 TTD Gene Abbreviation

T47101 TTD Target ID

Gene Info:

Publications:

Szlachcic A et al., 2012, FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation., Int J Nanomedicine

NCI: FGFR1

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Zheng et al., 2006, Vaccination with a recombinant chicken FGFR-1 bypasses immunological tolerance against self-FGFR-1 in mice., J. Huazhong Univ. Sci. Technol. Med. Sci.

Sáez et al., 1999, Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride., Prostate

Wetzler et al., 2006, Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation., Clin. Cancer Res.

DTC: FGFR1
- Version: 02-September-2020
Alternate Names:

Gene Info:

Publications:

Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.
HingoraniCasas: ENSG00000077782
- Version: 31-May-2017
Alternate Names:

ENSG00000077782 Gene Symbol

FGFR1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
TALC: FGFR1
- Version: 12-May-2016
Alternate Names:

FGFR1 Gene Symbol

Gene Info:

Publications:
TALC: FGFR-1
- Version: 12-May-2016
Alternate Names:

FGFR-1 Gene Symbol

Gene Info:

Publications:
MyCancerGenome: FGFR1
- Version: 20-Jun-2017
Alternate Names:

2260 Entrez Gene Id

FGFR1 MyCancerGenome Gene Symbol

FGFR1-3 MyCancerGenome Reported Gene Name

Gene Info:

Publications:
ChemblInteractions: BFGFR
- Version: chembl_23
Alternate Names:

CEK GENE_SYMBOL

FGFBR GENE_SYMBOL

FLG GENE_SYMBOL

Gene Info:

Publications:
OncoKB: FGFR1
- Version: 23-July-2020
Alternate Names:

2260 OncoKB Entrez Id

FLG OncoKB Gene Synonym

N-SAM OncoKB Gene Synonym

Gene Info:

Publications:
GO: FGFR1
- Version: 01-February-2022
Alternate Names:

BFGFR GO Gene Synonym

CEK GO Gene Synonym

FGFBR GO Gene Synonym

Gene Info:

Gene Categories:

TYROSINE KINASE

Publications:
Tempus: FGFR1
- Version: 11-November-2018
Alternate Names:

FGFR1 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
dGene: FGFR1
- Version: 27-Jun-2013
Alternate Names:

2260 Gene ID

BFGFR dGene Synonym

CD331 dGene Synonym

Gene Info:

Gene Categories:

KINASE, TYROSINE KINASE

Publications:
Pharos: FGFR1
- Version: 01-February-2022
Alternate Names:

Fibroblast growth factor receptor 1 Gene Name

P11362 UniProt ID

Gene Info:

Gene Categories:

KINASE

Publications:
ClearityFoundationClinicalTrial: FGFR1
- Version: 15-June-2013
Alternate Names:

Gene Info:

Publications:
MyCancerGenomeClinicalTrial: FGFR1
- Version: 30-February-2014
Alternate Names:

Gene Info:

Publications:
MskImpact: FGFR1
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FoundationOneGenes: FGFR1
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: FGFR1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: FGFR1
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Trial Name	FP-1039
Novel drug target	Established target
Indication/Tumor Type	lung cancer

Indication/Tumor Type	breast cancer
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive
Approval Status	Phase I

Trial Name	rHu-KGF, keratinocyte growth factor (KGF),Kepivance
Novel drug target	Established target

combination therapy	Alpelisib + Lucitanib
Indication/Tumor Type	estrogen-receptor positive breast cancer
Response Type	sensitive

Indication/Tumor Type	hemangioma
Evidence Type	Actionable
Approval Status	Phase I

Reported Cancer Type	Melanoma
Notes
Indication/Tumor Type	uterus leiomyosarcoma

Mechanism of Interaction	Fibroblast growth factor receptor inhibitor
Direct Interaction	yes

Notes
Indication/Tumor Type	extraosseous Ewing's sarcoma
Response Type	sensitive

Mechanism of Interaction	Fibroblast growth factor receptor 1 inhibitor
Direct Interaction	yes

Indication/Tumor Type	hepatocellular carcinoma
Response Type	no benefit
Approval Status	Preclinical - Cell culture

Indication/Tumor Type	pancreatic ductal adenocarcinoma
Response Type	predicted – sensitive
Approval Status	Clinical Study

Indication/Tumor Type	non-small cell lung carcinoma
Indication/Tumor Type	lung small cell carcinoma
Evidence Type	Actionable

combination therapy	AZD4547 + Vistusertib
Indication/Tumor Type	head and neck squamous cell carcinoma
Response Type	sensitive

combination therapy	AZD4547 + AZD8055
Indication/Tumor Type	lung adenocarcinoma
Response Type	sensitive

Evidence Type	Emerging
Approval Status	Phase II
Response Type	not applicable

combination therapy	AZD4547 + BKM120
Indication/Tumor Type	transitional cell carcinoma
Response Type	sensitive

Indication/Tumor Type	lung squamous cell carcinoma
Response Type	no benefit
Approval Status	Preclinical - Cell culture

combination therapy	Cisplatin + Etoposide + GSK3052230
Indication/Tumor Type	lung small cell carcinoma
Response Type	sensitive

combination therapy	AZD4547 + Sirolimus
Indication/Tumor Type	lung adenocarcinoma
Response Type	sensitive

FGFR1 Gene Record

FGFR1 2260 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Trial Name FP-1039 Novel drug target Established target Indication/Tumor Type lung cancer

PMIDs: 23226697 23536011

Sources: TdgClinicalTrial JAX-CKB TTD

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type breast cancer Response Type sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 7506125 27535969

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Phase I

PMIDs: 28341788 26324363 28965185

Sources: JAX-CKB TTD OncoKB

Interaction Types & Directionality: n/a

Interaction Info: Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance Novel drug target Established target

PMIDs: 11091737 10950949 9890894 11714710 10212269

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: combination therapy Alpelisib + Lucitanib Indication/Tumor Type estrogen-receptor positive breast cancer Response Type sensitive

PMIDs: 27126994 25193991

Sources: JAX-CKB ChemblInteractions CIViC MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type hemangioma Evidence Type Actionable Approval Status Phase I

PMIDs: 30807645

Sources: JAX-CKB ChemblInteractions CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 32315352

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Reported Cancer Type Melanoma Notes Indication/Tumor Type uterus leiomyosarcoma

PMIDs: 22837387 27870574 26015511 27535980

Sources: TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial TTD OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Fibroblast growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type no benefit Approval Status Preclinical

PMIDs: 22238366 20124951

Sources: JAX-CKB ChemblInteractions PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Indication/Tumor Type extraosseous Ewing's sarcoma Response Type sensitive

PMIDs: 24771645 22238366 26179511 23563700 23468082 26175911

Sources: TALC MyCancerGenome JAX-CKB CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Indication/Tumor Type Advanced Solid Tumor Response Type decreased response

PMIDs: 18559524 22238366 31016670

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Fibroblast growth factor receptor 1 inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type hepatocellular carcinoma Response Type no benefit Approval Status Preclinical - Cell culture

PMIDs: 26351320

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Evidence Type Actionable Approval Status Preclinical Response Type sensitive

PMIDs: 25295214 17943726

Sources: TdgClinicalTrial JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type pancreatic ductal adenocarcinoma Response Type predicted – sensitive Approval Status Clinical Study

PMIDs: 28476735

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type non-small cell lung carcinoma Indication/Tumor Type lung small cell carcinoma Evidence Type Actionable

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name FP-1039

Novel drug target Established target

Indication/Tumor Type lung cancer

PMIDs:
23226697 23536011

Sources:
TdgClinicalTrial JAX-CKB TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
7506125 27535969

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Phase I

PMIDs:
28341788 26324363 28965185

Sources:
JAX-CKB TTD OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
11091737 10950949 9890894 11714710 10212269

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy Alpelisib + Lucitanib

Indication/Tumor Type estrogen-receptor positive breast cancer

Response Type sensitive

PMIDs:
27126994 25193991

Sources:
JAX-CKB ChemblInteractions CIViC MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type hemangioma

Evidence Type Actionable

Approval Status Phase I

PMIDs:
30807645

Sources:
JAX-CKB ChemblInteractions CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
32315352

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Notes

Indication/Tumor Type uterus leiomyosarcoma

PMIDs:
22837387 27870574 26015511 27535980

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial TTD OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type no benefit

Approval Status Preclinical

PMIDs:
22238366 20124951

Sources:
JAX-CKB ChemblInteractions PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Indication/Tumor Type extraosseous Ewing's sarcoma

Response Type sensitive

PMIDs:
24771645 22238366 26179511 23563700 23468082 26175911

Sources:
TALC MyCancerGenome JAX-CKB CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Indication/Tumor Type Advanced Solid Tumor

Response Type decreased response

PMIDs:
18559524 22238366 31016670

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor 1 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type hepatocellular carcinoma

Response Type no benefit

Approval Status Preclinical - Cell culture

PMIDs:
26351320

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
25295214 17943726

Sources:
TdgClinicalTrial JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type pancreatic ductal adenocarcinoma

Response Type predicted – sensitive

Approval Status Clinical Study

PMIDs:
28476735

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Indication/Tumor Type lung small cell carcinoma

Evidence Type Actionable

PMIDs:
26438159

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

combination therapy	AZD4547 + Gefitinib
Indication/Tumor Type	head and neck squamous cell carcinoma
Response Type	sensitive

FGFR1	Display Id
ENSG00000077782	Ensembl Gene Id
BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 PRECURSOR (EC 2.7.1.112) (FGFR-1) (BFGF-R) (FMS-LIKE TYROSINE KINASE-2) (C-FGR). [SOURCE:UNIPROT/SWISSPROT;ACC:P11362]	Description

2260	Entrez Gene Id
FGFR1_HUMAN	Uniprot Id
ENSG00000077782	Ensembl Gene Id

2260	CKB Entrez Id
FGFR1	CKB Gene Synonym
bFGF-R-1	CKB Gene Synonym

2260	OncoKB Entrez Id
FLG	OncoKB Gene Synonym
N-SAM	OncoKB Gene Synonym

Fibroblast growth factor receptor 1	Gene Name
P11362	UniProt ID